Two separate leadership developments increased uncertainty across the gene therapy and CAR-T ecosystem. Legend Biotech said CEO Ying Huang abruptly resigned without naming a permanent replacement, appointing Alan Bash as interim CEO for Carvykti operations. In parallel, the sector also faced renewed FDA scrutiny of Capricor’s deramiocel in Duchenne, which added pressure to Capricor’s timeline and investor expectations. Together, the corporate and regulatory signals highlight how execution risk remains tightly linked to both management continuity and data/statistical consensus. The management moves will likely shape how quickly companies address operational questions while navigating advisory committee outcomes and ongoing development decisions.